Request Demo

Last update 08 May 2025

Hyperlipoproteinemia Type V

Last update 08 May 2025

Basic Info

Synonyms

5ｶﾞﾀｺｳｼｹｯｼｮｳ, 5ｶﾞﾀｺｳｼｹﾂｼｮｳ, 5ｶﾞﾀｺｳﾘﾎﾟﾀﾝﾊﾟｸｹｯｼｮｳ

+ [86]

Introduction

A severe type of hyperlipidemia, sometimes familial, that is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I .

Drugs associated with Hyperlipoproteinemia Type V

Recaticimab

Target

PCSK9

Mechanism

PCSK9 inhibitors

Active Org.

Guangdong Hengrui Pharmaceutical Co., Ltd. [+1]

Originator Org.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Active Indication

Complex dyslipidemia [+4]

Inactive Indication

Homozygous familial hypercholesterolemia [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

China

First Approval Date08 Jan 2025

Simvastatin

Target

HMGCR

Mechanism

HMG-CoA reductase inhibitors

Active Org.

Organon & Co. [+3]

Originator Org.

Merck Sharp & Dohme Corp.

Active Indication

Hyperlipoproteinemia Type V [+7]

Inactive Indication

Acute Coronary Syndrome [+12]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Australia

First Approval Date12 Sep 1991

Anacetrapib

Target

CETP

Mechanism

CETP inhibitors

Active Org.-

Originator Org.

Merck Sharp & Dohme Corp.

Active Indication-

Inactive Indication

Atherosclerosis [+11]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Hyperlipoproteinemia Type V

NCT05088759

/ Active, not recruitingNot ApplicableIIT

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management (LDL-ALERT)

A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values. The 400 patients will be comprised of 200 in the "Hospitalized Patient Cohort" and 200 in the "Outpatient Clinic Cohort." The allocation ratio will be 1:1 for an electronic alert-based CDS (EPIC BPA) notification versus no notification.

Start Date08 Oct 2021

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

NCT05085184

/ Unknown statusPhase 1

A Randomized, Open, Single-dose, 2x2x4 Replicate Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of UIC201806 and UIC201602 or Administration of UI018 in Healthy Volunteers

This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration.

Start Date06 Sep 2021

Sponsor / Collaborator

KOREA UNITED PHARM, Inc.

NCT04849000

/ CompletedPhase 3

Phase III, Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of SHR-1209 Monotherapy in Patients With Primary Hypercholesterolemia and Mixed Hyperlipemia

The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.

Start Date23 Apr 2021

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Hyperlipoproteinemia Type V

100 Translational Medicine associated with Hyperlipoproteinemia Type V

0 Patents (Medical) associated with Hyperlipoproteinemia Type V

267

Literatures (Medical) associated with Hyperlipoproteinemia Type V

01 Nov 2024·Journal of the American College of Cardiology

Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia

Article

Author: Sun, Jiao ; Ma, Liping ; Deng, Chanjuan ; Yan, Li ; Zhang, Xiwen ; Xu, Mingtong ; Han, Xuebin ; Xu, Biao ; Ling, Zhiyu ; Li, Liwen ; Yang, Ping ; Tian, Fengsheng ; Ge, Xiaofeng ; Ma, Likun ; Zhang, Yumin ; Hu, Xitian ; Ge, JunBo ; Luo, Suxin ; Huang, Zheng ; Liu, Zhiyuan ; Lv, Chao ; Luo, Li ; Lai, Chunlin ; Wang, Ying ; Sheng, Jianlong ; Wei, Wenhua ; Jin, Chunrong ; Wu, Yanqing ; Yin, Delu ; Li, Tianfa ; Han, Qinghua ; Zhao, Ruiping ; Yao, Zhuhua ; Wang, Zhen ; Feng, Wei ; Liu, Yong ; Huang, Rongjie

BACKGROUNDMonoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) have been used to reduce the level of low-density lipoprotein cholesterol (LDL-C), but require either biweekly or monthly dosing frequency. Recaticimab is a new humanized monoclonal antibody selectively targeting PCSK9, with long-acting characteristic.OBJECTIVESThe purpose of this study was to assess the efficacy and safety of recaticimab monotherapy in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk, and to explore different dosing strategies to provide patients with flexible administration options.METHODSThis was a randomized, double-blind, placebo-controlled, phase 3 study conducted at 59 sites in China. Patients with fasting LDL-C ≥2.6 to <4.9 mmol/L, fasting triglyceride ≤5.6 mmol/L, and 10-year ASCVD risk score <10% were randomly assigned (2:2:2:1:1:1) to receive subcutaneous injections of recaticimab at 150 mg every 4 weeks (Q4W), 300 mg every 8 weeks (Q8W), or 450 mg every 12 weeks (Q12W), or matching placebo, on background lipid-lowering diet. Primary endpoint was percentage change in LDL-C from baseline to week 12 for 150 mg Q4W and 450 mg Q12W and to week 16 for 300 mg Q8W.RESULTSA total of 703 patients underwent randomization and received recaticimab (n = 157, 156, and 155 for 150 mg Q4W, 300 mg Q8W, and 450 mg Q12W, respectively) or placebo (n = 78, 79, and 78, respectively). Compared with placebo, recaticimab further reduced LDL-C by 49.6% (95% CI: 44.2%-54.9%) at 150 mg Q4W, 52.8% (95% CI: 48.3%-57.2%) at 300 mg Q8W, and 45.0% (95% CI: 41.0%-49.0%) at 450 mg Q12W (P < 0.0001 for all comparisons). Safety with recaticimab was comparable to placebo. After 12 or 16 weeks of treatment, patients who received recaticimab continued treatment until week 24, whereas those allocated to placebo were switched to recaticimab treatment with the same dosing strategy. Both 24-week recaticimab and 12- or 8-week recaticimab switched from placebo were effective. With 24 weeks of recaticimab treatment, the most common treatment-related adverse event was injection site reaction (n = 23 [4.9%]).CONCLUSIONSRecaticimab monotherapy yielded significant LDL-C reductions and showed comparable safety vs placebo in patients with nonfamilial hypercholesterolemia and mixed hyperlipemia at low-to-moderate ASCVD risk, even with an infrequent dosing interval up to Q12W.

01 Oct 2024·Journal of Medical Ultrasound

Sonographic “Comet Tail” Artifacts in the Urinary Bladder in a Case of Type V Hyperlipidemia: A Previously Unreported Association

Article

Author: Mathur, Smriti ; Lahel, Ranjit Singh

The case pertains to a 29-year-old male who presented with epigastric pain at the hospital. On evaluation, he was sonographically detected to have “comet tail” reverberation artifacts involving the echogenic floaters in the lumen of the urinary bladder. The patient was subsequently diagnosed with Type V hyperlipidemia and acute pancreatitis. The association between this classic sonographic finding and hyperlipidemia has not been previously found documented in the available literature and hence merits a discussion of the relevant clinical details pertaining to the case.

05 Jul 2023·Cureus

A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment

Author: Alhuarrat, Majd Al Deen ; Faillace, Robert T ; Borkowski, Pawel ; Varrias, Dimitrios ; Kishore, Preeti ; Spanos, Michail ; Mangeshkar, Shaunak ; Nazarenko, Natalia ; Li, Weijia

Type V hyperlipoproteinemia or multifactorial chylomicronemia syndrome is a rare lipid disorder triggered mainly by uncontrolled diabetes, obesity, poor diet, or particular medications. It is associated with an increased risk of acute pancreatitis and accelerated coronary artery disease which may manifest in younger age groups. We present a case of a 42-year-old male who presented to the emergency department (ED) complaining of a non-healing hand injury. Upon laboratory workup, the patient was found to have an elevated total cholesterol (TC) of 1129 mg/dL, very low levels of high-density lipoprotein (HDL) and triglycerides (TG) > 4000 mg/dL with an inability to calculate low-density lipoprotein (LDL). Lipoprotein electrophoresis revealed an actual TG level of > 7000 mg/dL, increased chylomicrons, normal B and pre-B-lipoproteins, and increased L-lipoproteins with an elevated Apolipoprotein B. Despite these derangements, the patient did not exhibit any abdominal complaints, demonstrating a normal lipase level. The physical exam was indicative of bilateral arcus senilis and obesity. Insulin drip was initiated along with intravenous (IV) hydration and it required 12 days to bring triglycerides down to less than 1000 mg/dL. The total cholesterol was also seen to be down trending to around 500 mg/dL and the HDL improved to 22 mg/dL. We present this case as a unique presentation of asymptomatic chylomicronemia resistant to insulin treatment with an elevated ApoB but with no evidence of pancreatitis or coronary artery disease.

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hyperlipoproteinemia Type V

Basic Info

Related

Analysis